337. Liu, Y.; Tavana, O.; Gu, W. p53 modifications: Exquisite decorations of the powerful guardian. *J. Mol. Cell Biol.* **2019**, *11*, 564–577.
[CrossRef]

338. Suzuki, T.; Yokozaki, H.; Kuniyasu, H.; Hayashi, K.; Naka, K.; Ono, S.; Ishikawa, T.; Tahara, E.; Yasui, W. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. *Int. J. Cancer* **2000**, *88*, 992–997.
[CrossRef]

339. Terui, T.; Murakami, K.; Takimoto, R.; Takahashi, M.; Takada, K.; Murakami, T.; Minami, S.; Matsunaga, T.; Takayama, T.; Kato, J.; et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. *Cancer Res.* **2003**, *63*, 8948–8954.

340. Feng, L.; Pan, M.; Sun, J.; Lu, H.; Shen, Q.; Zhang, S.; Jiang, T.; Liu, L.; Jin, W.; Chen, Y.; et al. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. *J. Mol. Med.* **2013**, *91*, 49–58.
[CrossRef]

341. Sun, M.Y.; Zhang, H.; Tao, J.; Ni, Z.H.; Wu, Q.X.; Tang, Q.F. Expression and biological function of rhotekin in gastric cancer through regulating p53 pathway. *Cancer Manag. Res.* **2019**, *11*, 1069–1080.
[CrossRef] [PubMed]

342. Ma, Y.; Yue, Y.; Pan, M.; Sun, J.; Chu, J.; Lin, X.; Xu, W.; Feng, L.; Chen, Y.; Chen, D.; et al. Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer. *Am. J. Cancer Res.* **2015**, *5*, 663–673.

343. Spaety, M.E.; Gries, A.; Badie, A.; Venkatasamy, A.; Romain, B.; Orvain, C.; Yanagihara, K.; Okamoto, K.; Jung, A.C.; Mellitzer, G.; et al. HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. *Cancers.* **2019**, *11*, 1747.
[CrossRef] [PubMed]

344. Noguchi, A.; Kikuchi, K.; Zheng, H.; Takahashi, H.; Miyagi, Y.; Aoki, I.; Takano, Y. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. *Cancer Med.* **2014**, *3*, 1553–1561.
[CrossRef] [PubMed]

345. Hirai, S.; Endo, S.; Saito, R.; Hirose, M.; Ueno, T.; Suzuki, H.; Yamato, K.; Abei, M.; Hyodo, I. Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation. *PLoS ONE* **2014**, *9*, e102831.
[CrossRef]

346. Zhang, X.; Yashiro, M.; Ren, J.; Hirakawa, K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. *Oncol. Rep.* **2006**, *16*, 563–568.
[CrossRef]

347. Sasaki, Y.; Negishi, H.; Idogawa, M.; Suzuki, H.; Mita, H.; Toyota, M.; Shinomura, Y.; Imai, K.; Tokino, T. Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. *Mol. Cancer Ther.* **2008**, *7*, 779–787.
[CrossRef]

348. Qiu, H.; Yashiro, M.; Shinto, O.; Matsuzaki, T.; Hirakawa, K. DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells. *Cancer Sci.* **2009**, *100*, 181–188.
[CrossRef]

349. Shin, D.Y.; Sung Kang, H.; Kim, G.Y.; Kim, W.J.; Yoo, Y.H.; Choi, Y.H. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. *Biomed. Pharmacother.* **2013**, *67*, 305–311.
[CrossRef]

350. Shin, H.; Lee, Y.S.; Lee, Y.C. Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. *Oncol. Rep.* **2012**, *27*, 1111–1115.
[CrossRef]

351. Liu, J.; Xie, Y.S.; Wang, F.L.; Zhang, L.J.; Zhang, Y.; Luo, H.S. Cytotoxicity of 5-Aza-2'-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A). *Biomed. Pharmacother.* **2013**, *67*, 78–87.
[CrossRef] [PubMed]

352. Cheng, L.L.; Itahana, Y.; Lei, Z.D.; Chia, N.Y.; Wu, Y.; Yu, Y.; Zhang, S.L.; Thike, A.A.; Pandey, A.; Rozen, S.; et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). *Clin. Cancer Res.* **2012**, *18*, 4201–4212.
[CrossRef]

353. Bai, J.; Chen, J.; Ma, M.; Cai, M.; Xu, F.; Wang, G.; Tao, K.; Shuai, X. Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16. *DNA Cell Biol.* **2014**, *33*, 337–344.
[CrossRef]

354. Li, W.; Zhao, L.; Zang, W.; Liu, Z.; Chen, L.; Liu, T.; Xu, D.; Jia, J. Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. *Biochem. Biophys. Res. Commun.* **2011**, *416*, 372–378.
[CrossRef]

355. Xu, L.; Wu, W.; Cheng, G.; Qian, M.; Hu, K.; Yin, G.; Wang, S. Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression. *Technol. Cancer Res. Treat.* **2017**, *16*, 141–149.
[CrossRef]

356. Lee, K.H.; Park, J.W.; Sung, H.S.; Choi, Y.J.; Kim, W.H.; Lee, H.S.; Chung, H.J.; Shin, H.W.; Cho, C.H.; Kim, T.Y.; et al. PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer. *Oncogene* **2015**, *34*, 2897–2909.
[CrossRef] [PubMed]

357. Lee, J.H.; Yoo, N.J.; Kim, M.S.; Lee, S.H. Histone Demethylase Gene PHF2 Is Mutated in Gastric and Colorectal Cancers. *Pathol. Oncol. Res.* **2017**, *23*, 471–476.
[CrossRef]

358. Ohashi, M.; Kanai, F.; Ueno, H.; Tanaka, T.; Tateishi, K.; Kawakami, T.; Koike, Y.; Ikenoue, T.; Shiratori, Y.; Hamada, H.; et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. *Gut* **1999**, *44*, 366–371.
[CrossRef]

359. Takimoto, R.; Kato, J.; Terui, T.; Takada, K.; Kuroiwa, G.; Wu, J.; Ohnuma, H.; Takahari, D.; Kobune, M.; Sato, Y.; et al. Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor. *Cancer Biol. Ther.* **2005**, *4*, 421–428.
[CrossRef]

360. Xie, Y.S.; Zhang, Y.H.; Liu, S.P.; Liu, S.Q.; Peng, C.W.; Wu, L.; Luo, H.S.; Li, Y. Synergistic gastric cancer inhibition by chemo-genetherapy with recombinant human adenovirus p53 and epirubicin: An in vitro and in vivo study. *Oncol. Rep.* **2010**, *24*, 1613–1620.
361. Chen, G.X.; Zheng, L.H.; Liu, S.Y.; He, X.H. rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. *World J. Gastroenterol.* **WJG** **2011**, *17*, 4289–4297. [CrossRef] [PubMed]

362. Zhang, Y.; Shi, Y.; Li, X.; Du, W.; Luo, G.; Gou, Y.; Wang, X.; Guo, X.; Liu, J.; Ding, J.; et al. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer. *J. Gene Med.* **2010**, *12*, 147–156. [CrossRef] [PubMed]

363. Zhang, Y.F.; Zhang, B.C.; Zhang, A.R.; Wu, T.T.; Liu, J.; Yu, L.F.; Wang, W.X.; Gao, J.F.; Fang, D.C.; Rao, Z.G. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer. *Oncol. Rep.* **2013**, *30*, 1989–1995. [CrossRef]

364. Tsunemitsu, Y.; Kagawa, S.; Tokunaga, N.; Otani, S.; Umeoka, T.; Roth, J.A.; Fang, B.; Tanaka, N.; Fujiwara, T. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. *Gut* **2004**, *53*, 554–560. [CrossRef] [PubMed]

365. Dvory-Sobol, H.; Sagiv, E.; Liberman, E.; Kazanov, D.; Arber, N. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. *Cancer* **2007**, *109*, 188–197. [CrossRef]

366. Kunisaki, R.; Ikawa, S.; Maeda, T.; Nakazaki, Y.; Kurita, R.; Harata, M.; Shutoh, Y.; Bai, Y.S.; Soda, Y.; Tanabe, T.; et al. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate. *J. Gene Med.* **2006**, *8*, 1121–1130. [CrossRef]

367. Endo, S.; Yamato, K.; Hirai, S.; Moriwaki, T.; Fukuda, K.; Suzuki, H.; Abei, M.; Nakagawa, I.; Hyodo, I. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. *Cancer Sci.* **2011**, *102*, 605–613. [CrossRef] [PubMed]

368. Yi, H.; Yan, X.; Luo, Q.; Yuan, L.; Li, B.; Pan, W.; Zhang, L.; Chen, H.; Wang, J.; Zhang, Y.; et al. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. *J. Exp. Clin. Cancer Res.* **2018**, *37*, 97. [CrossRef] [PubMed]

369. Subhash, V.V.; Yeo, M.S.; Wang, L.; Tan, S.H.; Wong, F.Y.; Thuya, W.L.; Tan, W.L.; Peethala, P.C.; Soe, M.Y.; Tan, D.S.P.; et al. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. *Sci. Rep.* **2018**, *8*, 12248. [CrossRef]

370. Liu, X.; Wilcken, R.; Joerger, A.C.; Chuckowree, I.S.; Amin, J.; Spencer, J.; Fersht, A.R. Small molecule induced reactivation of mutant p53 in cancer cells. *Nucleic Acids Res.* **2013**, *41*, 6034–6044. [CrossRef]

371. Miller, J.J.; Orvain, C.; Jozi, S.; Clarke, R.M.; Smith, J.R.; Blanchet, A.; Gaiddon, C.; Warren, J.J.; Storr, T. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer. *Chemistry* **2018**, *24*, 17734–17742. [CrossRef] [PubMed]

372. Miller, J.J.; Blanchet, A.; Orvain, C.; Nouchikian, L.; Reviriot, Y.; Clarke, R.M.; Martelino, D.; Wilson, D.; Gaiddon, C.; Storr, T. Bifunctional ligand design for modulating mutant p53 aggregation in cancer. *Chem. Sci.* **2019**, *10*, 10802–10814. [CrossRef]

373. Wei, X.W.; Yuan, J.M.; Huang, W.Y.; Chen, N.Y.; Li, X.J.; Pan, C.X.; Mo, D.L.; Su, G.F. 2-Styryl-4-aminoquinazoline derivatives as potent DNA-cleavage, p53-activation and in vivo effective anticancer agents. *Eur. J. Med. Chem.* **2020**, *186*, 111851. [CrossRef]

374. Wischhusen, J.; Naumann, U.; Ohgaki, H.; Rastinejad, F.; Weller, M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. *Oncogene* **2003**, *22*, 8233–8245. [CrossRef] [PubMed]

375. Zhang, G.; Li, L.; Bi, J.; Wu, Y.; Li, E. Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway. *Eur. J. Pharmacol.* **2020**, *887*, 173584. [CrossRef] [PubMed]

376. Benosman, S.; Meng, X.; Von Grabowiecki, Y.; Palamiuc, L.; Hritcu, L.; Gross, I.; Mellitzer, G.; Taya, Y.; Loeffler, J.P.; Gaiddon, C. Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. *J. Biol. Chem.* **2011**, *286*, 43013–43025. [CrossRef]

377. Gaiddon, C.; Lokshin, M.; Ahn, J.; Zhang, T.; Prives, C. A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain. *Mol. Cell Biol.* **2001**, *21*, 1874–1887. [CrossRef]

378. Han, S.; Semba, S.; Abe, T.; Makino, N.; Furukawa, T.; Fukushige, S.; Takahashi, H.; Sakurada, A.; Sato, M.; Shiiba, K.; et al. Infrequent somatic mutations of the p73 gene in various human cancers. *Eur. J. Surg. Oncol.* **1999**, *25*, 194–198. [CrossRef] [PubMed]

379. Pilozzi, E.; Talerico, C.; Platt, A.; Fidler, C.; Ruco, L. p73 gene mutations in gastric adenocarcinomas. *Mol. Pathol.* **2003**, *56*, 60–62. [CrossRef]

380. Hamajima, N.; Matsuo, K.; Suzuki, T.; Nakamura, T.; Matsuura, A.; Hatooka, S.; Shinoda, M.; Kodera, Y.; Yamamura, Y.; Hirai, T.; et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. *Cancer Lett.* **2002**, *181*, 81–85. [CrossRef]

381. Shirai, O.; Ohmiya, N.; Taguchi, A.; Nakamura, M.; Kawashima, H.; Miyahara, R.; Itoh, A.; Hirooka, Y.; Watanabe, O.; Ando, T.; et al. P53, p21, and p73 gene polymorphisms in gastric carcinoma. *Hepatogastroenterology* **2010**, *57*, 1595–1601. [PubMed]

382. Liu, Y.; Dong, W.; Mou, Q.; Leng, Y.; Zhang, L.; Duan, L. Impact of p73 gene polymorphism on cancer susceptibility: A meta analysis. *Int. J. Clin. Exp. Pathol.* **2014**, *7*, 6820–6825. [PubMed]

383. Cheng, C.; Lingyan, W.; Yi, H.; Cheng, Z.; Huadan, Y.; Xuting, X.; Leiting, X.; Meng, Y.; Shiwei, D. Association between TLR2, MTR, MTRR, XPC, TP73, TP53 genetic polymorphisms and gastric cancer: A meta-analysis. *Clin. Res. Hepatol. Gastroenterol.* **2014**, *38*, 346–359. [CrossRef] [PubMed]

384. Shao, A.; Zheng, L.; Chen, S.; Gu, H.; Jing, H. p21, p53, TP53BP1 and p73 polymorphisms and the risk of gastric cardia adenocarcinoma in a Chinese population. *Biomarkers* **2015**, *20*, 109–115. [CrossRef] [PubMed]
385. De Feo, E.; Persiani, R.; La Greca, A.; Amore, R.; Arzani, D.; Rausei, S.; D'Ugo, D.; Magistrelli, P.; van Duijn, C.M.; Ricciardi, G.; et al. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. *Mutat. Res.* **2009**, *675*, 60–65. [CrossRef] [PubMed]

386. Tannapfel, A.; Schmelzer, S.; Benicke, M.; Klimpfinger, M.; Kohlhaw, K.; Mossner, J.; Engeland, K.; Wittekind, C. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer. *J. Pathol.* **2001**, *195*, 163–170. [CrossRef]

387. Carrasco, G.; Diaz, J.; Valbuena, J.R.; Ibanez, P.; Rodriguez, P.; Araya, G.; Rodriguez, C.; Torres, J.; Duarte, I.; Aravena, E.; et al. Overexpression of p73 as a tissue marker for high-risk gastritis. *Clin. Cancer Res.* **2010**, *16*, 3253–3259. [CrossRef]

388. Saavedra, K.; Valbuena, J.; Olivares, W.; Marchant, M.J.; Rodriguez, A.; Torres-Estay, V.; Carrasco-Avino, G.; Guzman, L.; Aguayo, F.; Roa, J.C.; et al. Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer. *PLoS ONE* **2015**, *10*, e0125834. [CrossRef]

389. Tomkova, K.; Belkhiri, A.; El-Rifai, W.; Zaika, A.I. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. *Cancer Res.* **2004**, *64*, 6390–6393. [CrossRef]

390. Vilgelm, A.; Wei, J.X.; Piazuelo, M.B.; Washington, M.K.; Prassolov, V.; El-Rifai, W.; Zaika, A. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. *Oncogene* **2008**, *27*, 2170–2176. [CrossRef]

391. Vilgelm, A.E.; Hong, S.M.; Washington, M.K.; Wei, J.; Chen, H.; El-Rifai, W.; Zaika, A. Characterization of DeltaNp73 expression and regulation in gastric and esophageal tumors. *Oncogene* **2010**, *29*, 5861–5868. [CrossRef] [PubMed]

392. Slade, N.; Zaika, A.I.; Erster, S.; Moll, U.M. DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. *Cell Death Differ.* **2004**, *11*, 357–360. [CrossRef] [PubMed]

393. Zaika, E.; Bhardwaj, V.; Wei, J.; Washington, M.K.; Souza, R.; El-Rifai, W.; Zaika, A. Proinflammatory cytokines and bile acids upregulate DeltaNp73 protein, an inhibitor of p53 and p73 tumor suppressors. *PLoS ONE* **2013**, *8*, e64306. [CrossRef] [PubMed]

394. Kang, M.J.; Park, B.J.; Byun, D.S.; Park, J.I.; Kim, H.J.; Park, J.H.; Chi, S.G. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. *Clin. Cancer Res.* **2000**, *6*, 1767–1771. [PubMed]

395. Ushiku, T.; Chong, J.M.; Uozaki, H.; Hino, R.; Chang, M.S.; Sudo, M.; Rani, B.R.; Sakuma, K.; Nagai, H.; Fukayama, M. p73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. *Int. J. Cancer* **2007**, *120*, 60–66. [CrossRef]

396. Okada, T.; Nakamura, M.; Nishikawa, J.; Sakai, K.; Zhang, Y.; Saito, M.; Morishige, A.; Oga, A.; Sasaki, K.; Suehiro, Y.; et al. Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas. *Cancer Sci.* **2013**, *104*, 1309–1314. [CrossRef] [PubMed]

397. Wei, J.; O'Brien, D.; Vilgelm, A.; Piazuelo, M.B.; Correa, P.; Washington, M.K.; El-Rifai, W.; Peek, R.M.; Zaika, A. Interaction of *Helicobacter pylori* with gastric epithelial cells is mediated by the p53 protein family. *Gastroenterology* **2008**, *134*, 1412–1423. [CrossRef]

398. Luo, J.; Chen, X.Q.; Li, P. The Role of TGF-beta and Its Receptors in Gastrointestinal Cancers. *Transl. Oncol.* **2019**, *12*, 475–484. [CrossRef] [PubMed]

399. Ma, G.F.; Miao, Q.; Zeng, X.Q.; Luo, T.C.; Ma, L.L.; Liu, Y.M.; Lian, J.J.; Gao, H.; Chen, S.Y. Transforming growth factor-beta1 and -beta2 in gastric precancer and cancer and roles in tumor-cell interactions with peripheral blood mononuclear cells in vitro. *PLoS ONE* **2013**, *8*, e54249. [CrossRef]

400. Yamamura, Y.; Lee, W.L.; Goh, M.X.; Ito, Y. Role of TAp73alpha in induction of apoptosis by transforming growth factor-beta in gastric cancer cells. *FEBS Lett.* **2008**, *582*, 2663–2667. [CrossRef] [PubMed]

401. Yuan, Z.M.; Shioya, H.; Ishiko, T.; Sun, X.; Gu, J.; Huang, Y.Y.; Lu, H.; Kharbanda, S.; Weichselbaum, R.; Kufe, D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. *Nature* **1999**, *399*, 814–817. [CrossRef]

402. Pediconi, N.; Ianari, A.; Costanzo, A.; Belloni, L.; Gallo, R.; Cimino, L.; Porcellini, A.; Screpanti, I.; Balsano, C.; Alesse, E.; et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. *Nat. Cell Biol.* **2003**, *5*, 552–558. [CrossRef]

403. Urist, M.; Tanaka, T.; Poyurovsky, M.V.; Prives, C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. *Genes Dev.* **2004**, *18*, 3041–3054. [CrossRef]

404. Qiang, L.; Ji, Z.; Wang, X. Expression of TAp73alpha affects the therapy effect of chemotherapy drugs in gastric cancer. *Oncol. Res.* **2018**. [CrossRef] [PubMed]

405. Ji, Z.P.; Qiang, L.; Zhang, J.L. Transcription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancer. *Exp. Ther. Med.* **2018**, *15*, 1831–1838. [CrossRef]

406. Tang, S.; Yuan, Y.; Liu, Z.; He, Y.; Pan, D. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis. *Biochem. Biophys. Res. Commun.* **2020**, *530*, 686–691. [CrossRef] [PubMed]

407. Li, L.; Li, L.; Li, W.; Chen, T.; Bin, Z.; Zhao, L.; Wang, H.; Wang, X.; Xu, L.; Liu, X.; et al. TAp73-induced phosphofructokinase-1 transcription promotes the Warburg effect and enhances cell proliferation. *Nat. Commun.* **2018**, *9*, 4683. [CrossRef]

408. Wang, H.; Liu, Z.; Li, J.; Zhao, X.; Wang, Z.; Xu, H. DeltaNp63alpha mediates proliferation and apoptosis in human gastric cancer cells by the regulation of GATA-6. *Neoplasma* **2012**, *59*, 416–423. [CrossRef] [PubMed]

409. Song, Y.; Liu, D.; He, G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. *Cancer Biomark.* **2015**, *15*, 591–597. [CrossRef]

410. Glickman, J.N.; Yang, A.; Shahsafaei, A.; McKeon, F.; Odze, R.D. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. *Hum. Pathol.* **2001**, *32*, 1157–1165. [CrossRef]
411. Ye, F.; Tang, C.; Shi, W.; Qian, J.; Xiao, S.; Gu, M.; Dang, Y.; Liu, J.; Chen, Y.; Shi, R.; et al. A MDM2-dependent positive-feedback loop is involved in inhibition of miR-375 and miR-106b induced by *Helicobacter pylori* lipopolysaccharide. *Int. J. Cancer* **2015**, *136*, 2120–2131. [CrossRef] [PubMed]

412. Hoebe, E.; Wille, C.; Hagemeier, S.; Kenney, S.; Greijer, A.; Middeldorp, J. Epstein-Barr Virus Gene BARF1 Expression is Regulated by the Epithelial Differentiation Factor DeltaNp63alpha in Undifferentiated Nasopharyngeal Carcinoma. *Cancers*. **2018**, *10*, 76. [CrossRef] [PubMed]